Novartis suspended the program. Three serious cases of immune-effector cell-related hemophagocytic syndrome have previously been reported. Complications eventually led to the death of patients.

Novartis suspended the program. Three serious cases of immune-effector cell-related hemophagocytic syndrome have previously been reported. Complications eventually led to the death of patients.